Home » The Medicines Company Discontinues Development of MDCO-216
The Medicines Company Discontinues Development of MDCO-216
The Medicines Company has terminated the clinical development program for MDCO-216, its investigational cholesterol efflux promoter.
Data from the pilot trial did not show drug effects on intracoronary atherosclerotic plaque sufficient to warrant further development.
Upcoming Events
-
25Apr
-
07May
-
14May
-
30May